Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

David Hamon

Clinical Cardiac Electrophysiology Iowa City, IA Medical Doctor

NPI 1487317061 CMS profile 11257598

200 Hawkins Dr, Iowa City, IA 52242

Open in the dashboard

General payments

$10,516

242 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Hamon of Iowa City, IA is reported in the CMS Open Payments database as having received $10,516 across 242 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,507 124
2024 General $1,322 78
2023 General $641 37
2022 General $46 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Hamon
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to David Hamon were reported at $8,507. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year David Hamon Clinical Cardiac Electrophysiology median Middle half National median
2019 $0 $2,361 $585–$8,260 $163
2020 $0 $993 $247–$4,351 $114
2021 $0 $1,185 $326–$4,739 $132
2022 $46 $2,073 $554–$6,789 $149
2023 $641 $2,568 $759–$8,159 $160
2024 $1,322 $2,557 $703–$7,403 $164
2025 $8,507 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Abbott Laboratories $7,352 75 payments
  2. Boston Scientific Corporation $2,104 143 payments
  3. Medtronic, Inc. $748 12 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $73 1 payment
  5. Cardiva Medical, Inc. $59 2 payments
  6. Impulse Dynamics (USA) Inc. $48 2 payments
  7. Philips Electronics North America Corporation $42 1 payment
  8. Aziyo Biologics, Inc. $38 3 payments
  9. Biosense Webster, Inc. $31 2 payments
  10. Itamar Medical Inc $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $5,260 1 payment
  2. Food and Beverage $3,957 233 payments
  3. Travel and Lodging $1,299 8 payments
Products named General payments · program years 2022–2025
  1. TACTICATH ABLATION CATHETER, SENSOR ENABLED $6,056 8 payments
  2. EVERA MRI XT DR SURESCAN $582 6 payments
  3. RESONATE EL ICD VR $486 37 payments
  4. AVEIR $357 11 payments
  5. ENSITE Structural Heart $262 14 payments
  6. ENSITE Electrophysiology $222 7 payments
  7. EMBLEM MRI S-ICD $186 17 payments
  8. CDS - Other $155 10 payments
  9. INGEVITY+ $123 9 payments
  10. ACCOLADE SR $114 6 payments
  11. Other $1,559 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

758

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$217,631

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

38%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 163 $145,833
Xarelto Rivaroxaban Brand 33 $43,894
Multaq Dronedarone Hcl Brand 16 $12,262
Dofetilide Generic 13 $5,367
Flecainide Acetate Generic 138 $5,283
Amiodarone Hcl Generic 122 $1,886
Metoprolol Succinate Generic 121 $1,565
Sotalol Sotalol Hcl Brand 65 $1,084
Metoprolol Tartrate Generic 61 $290
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 11 $121

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$149,125

Medicare's payments for the services billed

Medicare patients

1,313

Average age 74

Services billed

2,235

596 women, 717 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 49%
Arthritis 42%
Heart failure 40%
Ischemic heart disease 40%
Chronic kidney disease 33%
Diabetes 32%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record